Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases

被引：41

作者：

Braun, Thorsten ^{[1
]}

de Botton, Stephane ^{[2
,6
]}

Taksin, Anne-Laure ^{[3
]}

Park, Sophie ^{[4
]}

Beyne-Rauzy, Odile ^{[5
]}

Coiteux, Valerie ^{[6
]}

Sapena, Rosa ^{[4
]}

Lazareth, Anne ^{[1
]}

Leroux, Genevieve ^{[7
]}

Guenda, Khaled ^{[1
]}

Cassinat, Bruno ^{[8
]}

Fontenay, Michaela ^{[9
]}

Vey, Norbert ^{[10
]}

Guerci, Agnes ^{[11
]}

Dreyfus, Francois ^{[4
]}

Bordessoule, Dominique ^{[12
]}

Stamatoullas, Aspasia ^{[13
]}

Castaigne, Sylvie ^{[3
]}

Terre, Christine ^{[14
]}

Eclache, Virginie ^{[7
]}

Fenaux, Pierre ^{[1
]}

Ades, Lionel ^{[1
]}

机构：

[1] Univ Paris 08, Hop Avicenne, AP HP, Serv Hematol Clin, F-93009 Bobigny, France

[2] Inst Gustave Roussy, Serv Hematol Clin, Villejuif, France

[3] Hop Andre Mignot, CH Versailles, Serv Hematol Clin, Le Chesnay, France

[4] Univ Paris 05, Hop Cochin, AP HP, Serv Hematol Clin, F-75270 Paris 06, France

[5] Hop Purpan, Serv Med Interne, Toulouse, France

[6] CHRU Lille, Serv Malad Sang, Lille, France

[7] Univ Paris 08, Hop Avicenne, AP HP, Hematol Lab, F-93009 Bobigny, France

[8] Univ Paris 07, Hop St Louis, AP HP, Hematol Lab, Paris, France

[9] Univ Paris 05, Hop Cochin, AP HP, Hematol Lab, Paris, France

[10] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[11] CHU Nancy, Serv Hematol, Nancy, France

[12] CHU Dupuytren, Serv Hematol Clin & Therapie Cellulaire, Limoges, France

[13] CHU Rouen, Serv Hematol, Rouen, France

[14] Hop Andre Mignot, CH Versailles, Lab Cytogenet, Le Chesnay, France

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 07期

关键词：

Myelodysplastic syndromes; Del; 20q; Immunologic thrombocytopenic purpura; Thrombocytopenia; WHO classification; WORLD-HEALTH-ORGANIZATION; MYELOID MALIGNANCIES; THROMBOCYTOPENIC PURPURA; CLASSIFICATION; PROGNOSIS; IDENTIFICATION; NEOPLASMS; FEATURES;

D O I：

10.1016/j.leukres.2011.02.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Isolated 20q deletion is common in MDS and considered of good prognosis, but no large series have been reported. We compared characteristics of 62 MDS patients with isolated del 20q, 36 patients with del 20q and other cytogenetic abnormalities, and 1335 MDS patients without del20q. Significant differences between MDS with isolated del 20q and patients without del 20q were lower platelet count (mean 144 vs. 196 G/l, p = 0.005), lower marrow blast count (mean 3.9% vs. 5.6%, p = 0.0008), and higher reticulocyte count (mean 72.5 vs. 51.7 G/l, p = 0.04). Ten (16%) patients with isolated del 20q had Hb > 12 g/dl and platelets <100 G/l, compared to 7.3% of patients without del 20q (p = 0.025). Review of marrow slides of those 10 patients showed that could be readily identified as MDS prior to cytogenetics. Fourteen percent of patients with isolated del 20q progressed to AML compared to 11% with one and 24% with several additional abnormalities. Median survival was 54 months in patients with isolated del 20q, not reached and 12 months for del 20q with one and several additional abnormalities, respectively (p = 0.035) confirming the favorable prognosis of del 20q without complex abnormalities. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：863 / 867

页数：5

共 20 条

[1] Association between myeloid malignancies and acquired deficit in protein 4.1R:: A retrospective analysis of six patients [J].

Alanio-Brechot, Cecile ;

Schischmanoff, Pierre-Olivier ;

Feneant-Thibault, Madeleine ;

Cynober, Therese ;

Tchernia, Gil ;

Delaunay, Jean ;

Garcon, Loic .

AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (04) :275-278

[2] Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes [J].

Bench, AJ ;

Nacheva, EP ;

Hood, TL ;

Holden, JL ;

French, L ;

Swanton, S ;

Champion, KM ;

Li, J ;

Whittaker, P ;

Stavrides, G ;

Hunt, AR ;

Huntly, BJP ;

Campbell, LJ ;

Bentley, DR ;

Deloukas, P ;

Green, AR .

ONCOGENE, 2000, 19 (34) :3902-3913

[3]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[4]

BOULTWOOD J, 1994, BLOOD, V84, P3253

[5] Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases [J].

Bourgeois, E ;

Caulier, MT ;

Rose, C ;

Dupriez, B ;

Bauters, F ;

Fenaux, P .

LEUKEMIA, 2001, 15 (06) :950-953

[6]

Brunning RD, 2001, WHO CLASSIFICATION T, P61

[7] Myelodysplastic syndromes: From pathogenesis and prognosis to treatment [J].

Fenaux, P .

SEMINARS IN HEMATOLOGY, 2004, 41 (02) :6-12

[8] Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 [J].

Giagounidis, AAN ;

Germing, U ;

Haase, S ;

Hildebrandt, B ;

Schlegelberger, B ;

Schoch, C ;

Wilkens, L ;

Heinsch, M ;

Willems, H ;

Aivado, M ;

Aul, C .

LEUKEMIA, 2004, 18 (01) :113-119

[9] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[10] Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation [J].

Gupta, Raavi ;

Soupir, Chad P. ;

Johari, Vandita ;

Hasserjian, Robert P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :265-268

← 1 2 →